Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker-Reply

Cristina Valero¹, Timothy A Chan^{2

3}, Luc G T Morris¹

Affiliations

¹ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
² Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.
³ Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

Comment

Cristina Valero et al. JAMA Oncol. 2021.

. 2021 Aug 1;7(8):1245-1246.

doi: 10.1001/jamaoncol.2021.1870.

Cristina Valero¹, Timothy A Chan^{2

3}, Luc G T Morris¹

¹ Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
² Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, Ohio.
³ Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio.

No abstract available

Comment on

Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C, Lee M, Hoen D, Zehir A, Berger MF, Seshan VE, Chan TA, Morris LGT. Valero C, et al. JAMA Oncol. 2021 May 1;7(5):739-743. doi: 10.1001/jamaoncol.2020.7684. JAMA Oncol. 2021. PMID: 33599686 Free PMC article.
Inappropriate Use of the Same Cutoff by Different Sequencing Panels for Tumor Mutation Burden as Immunotherapy Biomarker.
Cui L, Zhang F. Cui L, et al. JAMA Oncol. 2021 Aug 1;7(8):1244-1245. doi: 10.1001/jamaoncol.2021.1867. JAMA Oncol. 2021. PMID: 34110373 No abstract available.